BRIEF-VBL Therapeutics reports positive review of late-stage trial for glioblastoma drug
April 20 Vascular Biogenics Ltd-
* VBL Therapeutics announces positive dsmc review in phase 3 globe trial investigating vb-111 in RGBM
* Vascular Biogenics Ltd - currently expect globe trial interim analysis to occur in mid-2017
* Vascular Biogenics Ltd - top-line results from full dataset to be available in early 2018.
* Vascular Biogenics - committee reviewed globe safety data and unanimously recommended that study continue as planned
* Vascular Biogenics - committee reviewed globe safety data and unanimously recommended that study continue as planned Source text for Eikon: Further company coverage: